← Back to Clinical Trials
Recruiting NCT07578896

NCT07578896 Maze Balance Board Training Effects on Mobility and Motor Skills in Cognitively Impaired Children

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07578896
Status Recruiting
Phase
Sponsor Riphah International University
Condition Cognitive Impairment
Study Type INTERVENTIONAL
Enrollment 22 participants
Start Date 2025-10-28
Primary Completion 2026-05-05

Eligibility & Interventions

Sex All sexes
Min Age 6 Years
Max Age 10 Years
Study Type INTERVENTIONAL
Interventions
Maze Balance Board traingConventional Physical Therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 22 participants in total. It began in 2025-10-28 with a primary completion date of 2026-05-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study will be a Randomized Controlled Trial including 22 children aged 6-10 years with deficits in functional mobility and gross motor skills. Participants will be randomly divided into an experimental group (n=11), receiving a seven-stage progressive Maze Balance Board protocol, and a control group (n=11), receiving conventional physical therapy. Both groups will undergo 30-minute sessions, three times per week, for 8 weeks. Eligible participants will be enrolled after guardian consent. Outcomes will be assessed using the Montreal Cognitive Assessment (MoCA) for cognition, Timed Up and Go (TUG) test for functional mobility, and Bruininks-Oseretsky Test of Motor Proficiency, Second Edition (BOT-2) for gross motor skills. Ethical approval will be obtained from Riphah International University, Lahore, and data will be analyzed using SPSS version 27.0.

Eligibility Criteria

Inclusion Criteria: * Children aged 6-10 years * Mild to Moderate Cognitive Impairment (MoCA score =18 to 25) * Gross motor skill delay (10). * Ability to follow verbal instructions * Parents are willing to make sure their child's participation Exclusion Criteria: * Use of medications that may influence neuromotor functions (e.g., sedatives, antiepileptic's) * Children with visual and hearing impairments * Receiving concurrent therapies * Recent lower limb injuries , surgeries, or musculoskeletal conditions

Contact & Investigator

Central Contact

Imran Amjad, MS-PT

✉ imran.amjad@riphah.edu.pk

📞 9233224390125

Principal Investigator

Maryam Shafique, MS-PT

PRINCIPAL INVESTIGATOR

Riphah International University Lahore

Frequently Asked Questions

Who can join the NCT07578896 clinical trial?

This trial is open to participants of all sexes, aged 6 Years or older, up to 10 Years, studying Cognitive Impairment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07578896 currently recruiting?

Yes, NCT07578896 is actively recruiting participants. Contact the research team at imran.amjad@riphah.edu.pk for enrollment information.

Where is the NCT07578896 trial being conducted?

This trial is being conducted at Lahore, Pakistan.

Who is sponsoring the NCT07578896 clinical trial?

NCT07578896 is sponsored by Riphah International University. The principal investigator is Maryam Shafique, MS-PT at Riphah International University Lahore. The trial plans to enroll 22 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology